Established in December 2018, MinneBio has evolved into a sustainable supplier in biotechnology, specializing in enzymes such as ultra-active nuclease (Benzonase), proteinase K, and cytokines like human interleukins-2, 6, 10, 12, 15, and cell culture media. Our products serve academic research, therapeutic trials, and pharmaceutical development, ensuring reliability and quality. Committed to customer satisfaction, we offer the best solutions with our advanced platform for peptides, proteins, and antibodies, tailored to meet specific customer requirements. At MinneBio, we prioritize customer needs by actively listening and delivering exceptional products and services.
| Website | https://www.minnebio.com |
| Employees | 2 (1 on RocketReach) |
| Founded | 2018 |
| Industry | Biotechnology Research |
| Keywords | Enzymes, Biotechnology, Sustainable Biotechnology, Cell Culture, Biochemicals, Research Reagents, Laboratory Reagents, Molecular Biology, Bioprocessing, Pharmaceutical Ingredients |
Looking for a particular MinneBio employee's phone or email?
MinneBio Questions
David Liang is the CEO of MinneBIO || Editor of Computational and Structural Biotechnology Journal of MinneBio.
1 people are employed at MinneBio.
Top MinneBio Employees
Related Companies
